


In the claims:

1. (currently amended) A compound of formula




wherein

R₁ and R_{1'} are hydrogen or deuterium,


R₂, R₃ and R₄ are hydrogen or deuterium,

R₅ is the residue of an alpha amino acid, wherein the N which is part of the ring in formula I is acylated by the carboxylic group of said amino acid and wherein the carbonyl group of said amino acid is bound to the nitrogen of the group of formula



and the -OH group of said amino acid function is missing,

X is S or N-ALK,




the group of formula


is piperidinyl or tetrahydropyridinyl,

ALK is (C₁₋₄)alkyl, and

R_6 is hydrogen, hydroxy or (C_{2-12})acyloxy,

with the proviso that if



the group  is piperidinyl and X is S, then R_6 is other than hydrogen.

2. (original) A compound according to claim 1 which is selected from the group consisting of

14-O-[4-hydroxy-N-valyl-piperidin-3-yl]-sulfanylacetymutilin,

14-O-[3-hydroxy-N-valyl-piperidin-4-yl]-sulfanylacetymutilin,

14-O-[3-hydroxy-N-histidinyl-piperidin-4-yl]-sulfanylacetymutilin,


14-O-[3-hydroxy-N-valyl-piperidin-4-yl]-methylaminoacetylutilin,

14-O-[4-hydroxy-N-valyl-piperidin-3-yl]-methylaminoacetylutilin,

14-O-[N-valyl]-1,2,3,6-tetrahydropyridin-3-yl]-sulfanylacetymutilin, and

14-O-[N-valyl]-1,4,5,6-tetrahydropyridin-4-yl]-sulfanylacetymutilin.

3. (currently amended) A compound of formula




wherein

R_1 and R_1' are hydrogen or deuterium,


R_2 , R_3 and R_4 are hydrogen or deuterium,

R₇ is a protecting group or the residue of an alpha amino acid, wherein the N which is part of the ring in formula II is acylated by the carboxylic group of said amino acid and wherein the carbonyl group of said amino acid is bound to the nitrogen of the group of formula



and said amino acid function is devoid of the -OH group, and wherein the amino group is protected,

X is S or N-ALK,




the group of formula

is piperidinyl or tetrahydropyridinyl,

ALK is (C_{1-4})alkyl, and

R₈ is hydrogen, hydroxy or (C₂₋₁₂)acyloxy,

with the proviso that if



the group of formula

is piperidinyl and X is S, then R₈ is other than hydrogen.

4. (original) A compound according to claim 3 selected from the group consisting of

14-O-[N-BOC-4-hydroxy-piperidin-3-yl]-sulfanylacetymutilin,
14-O-[N-BOC-3-hydroxy-piperidin-4-yl]-sulfanylacetymutilin,
14-O-[4-hydroxy-N-BOC-piperidin-3-yl]- methylaminoacetylmutilin,
14-O-[3-hydroxy-N-BOC-piperidin-4-yl]-methylaminoacetylmutilin,
14-O-[N-BOC-1,4,5,6-tetrahydropyridin-4-yl]- sulfanylacetymutilin,
14-O-[4-hydroxy-N-(N-BOC-valyl)-piperidin-3-yl]-sulfanylacetymutilin,
14-O-[3-hydroxy-N-(N-BOC-valyl)-piperidin-4-yl]-sulfanylacetymutilin,
14-O-[4-acetoxy-N-(N-BOC-valyl)-piperidin-3-yl]-sulfanylacetymutilin,
14-O-[3-acetoxy-N-(N-BOC-valyl)-piperidin-4-yl]-sulfanylacetymutilin,
14-O-[3-hydroxy-N-(N-BOC-histidinyl)-piperidin-4-yl]-sulfanylacetymutilin,
14-O-[3-hydroxy-N-(N-BOC)-valyl-piperidin-4-yl]- methylaminoacetylmutilin,
14-O-[4-hydroxy-N-(N-BOC)-valyl-piperidin-3-yl]- methylaminoacetylmutilin,
14-O-[N-(N-BOC-valyl)-1,4,5,6-tetrahydropyridin-4-yl]- sulfanylacetymutilin,
14-O-[N-(N-BOC-valyl)-1,2,3,6-tetrahydropyridin-3-yl]- sulfanylacetymutilin.

5. (previously presented) A compound of claim 1 in the form of a salt.

6. (canceled)

7. (previously presented) A pharmaceutical composition comprising a compound of claim 1 in association with at least one pharmaceutical excipient.

8. (original) A pharmaceutical composition according to claim 7 further comprising another pharmaceutically active agent.

9. (canceled)

10. (previously presented) A method of treatment of microbial diseases comprising administering to a subject in need of such treatment an effective amount of a compound of claim 1.